As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Any use of trade names in this program is for reference purposes only. No promotion of particular products or devices should be inferred.

Moderator(s)

Gregg W. Stone, MD

Professor of Medicine; Director, Cardiovascular Research and Education, Center for Interventional Vascular Therapy, New York-Presbyterian Hospital, Columbia University Medical Center; Co-Director, Medical Research and Education Division, The Cardiovascular Research Foundation, New York, NY

Disclosures

Disclosure: Gregg W. Stone, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Osprey Pharmaceuticals USA; REVA Medical, Inc.; Merck & Co., Inc.; Abbott Laboratories; Boston Scientific; AstraZeneca Pharmaceuticals LP; Eli Lilly and Company; Daiichi Sankyo, Inc.; Bristol-Myers Squibb Company; Otsuka Pharmaceutical Co., Ltd.; Gilead Sciences, Inc.; InspireMD Ltd.; TherOx, Inc.; The Medicines Company; Atrium Medical Corporation; InfraReDx, Inc.; Volcano Corporation; Medtronic, Inc.
Served as a speaker or a member of a speakers bureau for: Vascular Solutions, Inc.
Owns stock, stock options, or bonds from: Medtronic, Inc.; Ovalum LTD.; FlowCardia, Inc.; Caliber Therapeutics, Inc.; Arstasis; MiCardia Corporation; AccessClosure, Inc.; Embrella Cardiovascular™, Inc.; Guided Delivery Systems, Inc.; Biostar funds; Medfocus funds

Dr. Stone does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the US Food and Drug Administration (FDA) for use in the United States.

Dr. Stone does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Panelist(s)

Sunil V. Rao, MD

Assistant Professor of Medicine, Duke University Medical Center; Director, Cardiac Catheterization Laboratories, Durham VA Medical Center, Durham, North Carolina

Disclosures

Disclosure: Sunil V. Rao, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bristol-Myers Squibb Company; AstraZeneca Pharmaceuticals LP; The Medicines Company; Terumo Medical Corporation; Daiichi Sankyo, Inc.; Eli Lilly and Company
Served as a speaker or a member of a speakers bureau for: Bristol-Myers Squibb Company; sanofi-aventis; The Medicines Company; Terumo Medical Corporation
Received grants for clinical research from: Cordis Corporation; Novartis Pharmaceuticals Corporation; Ikaria, Inc.

Dr. Rao does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr. Rao does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

James B. Hermiller, MD

Director, Cardiac Catheterization Labs, The Care Group, St. Vincent Hospital, Indianapolis, Indiana

Disclosures

Disclosure: James B. Hermiller, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: St. Jude Medical; Boston Scientific; Abbott Laboratories; Medtronic, Inc.
Served as a speaker or a member of a speakers bureau for: Eli Lilly and Company

Dr. Hermiller does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr. Hermiller does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Alan Kadish, MD

Chester C. and Deborah H. Cooley Distinguished Professor of Cardiology and Medicine, Feinberg Cardiovascular Institute, Northwestern University, Chicago, Illinois

Disclosures

Disclosure: Alan Kadish, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: LifeWatch, Corp.; sanofi-aventis
Received grants for clinical research from: St. Jude Medical

Dr. Kadish does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr. Kadish does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor(s)

Ronald K. Miller, PhD

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Ronald K. Miller, PhD, has disclosed no relevant financial relationships.

CME Reviewer(s)

Nafeez Zawahir, MD

CME Clinical Director, Medscape, LLC

Disclosures

Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

CME

Prevention of Sudden Cardiac Arrest Post PTCA in High-Risk Patients

Authors: Gregg W. Stone, MD; Sunil V. Rao, MD; James B. Hermiller, MD; Alan Kadish, MD
CME Released: 4/29/2011; Reviewed and Renewed: 9/2/2015
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 9/2/2016, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This activity is intended for electrophysiologists, interventional cardiologists, clinical cardiologists, and other allied healthcare professionals.

The goal of this activity is to enhance the ability to protect patients at high risk for sudden cardiac death immediately after percutaneous coronary intervention without using inappropriate implantable cardioverter-defibrillator therapy.

Upon completion of this activity, participants will be able to:

Define the risk for sudden cardiac arrest (SCA) following percutaneous transluminal coronary angioplasty (PTCA), especially in patients at high risk
Assess the role of wearable defibrillators in the management of patients at risk for SCA following PTCA
Implement optimal strategies to reduce the risk for SCA post PTCA at the time of hospital discharge

Disclosures

Any use of trade names in this program is for reference purposes only. No promotion of particular products or devices should be inferred.

Moderator(s)

Gregg W. Stone, MD

Professor of Medicine; Director, Cardiovascular Research and Education, Center for Interventional Vascular Therapy, New York-Presbyterian Hospital, Columbia University Medical Center; Co-Director, Medical Research and Education Division, The Cardiovascular Research Foundation, New York, NY

Disclosures

Disclosure: Gregg W. Stone, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Osprey Pharmaceuticals USA; REVA Medical, Inc.; Merck & Co., Inc.; Abbott Laboratories; Boston Scientific; AstraZeneca Pharmaceuticals LP; Eli Lilly and Company; Daiichi Sankyo, Inc.; Bristol-Myers Squibb Company; Otsuka Pharmaceutical Co., Ltd.; Gilead Sciences, Inc.; InspireMD Ltd.; TherOx, Inc.; The Medicines Company; Atrium Medical Corporation; InfraReDx, Inc.; Volcano Corporation; Medtronic, Inc.
Served as a speaker or a member of a speakers bureau for: Vascular Solutions, Inc.
Owns stock, stock options, or bonds from: Medtronic, Inc.; Ovalum LTD.; FlowCardia, Inc.; Caliber Therapeutics, Inc.; Arstasis; MiCardia Corporation; AccessClosure, Inc.; Embrella Cardiovascular™, Inc.; Guided Delivery Systems, Inc.; Biostar funds; Medfocus funds

Dr. Stone does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the US Food and Drug Administration (FDA) for use in the United States.

Dr. Stone does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Panelist(s)

Sunil V. Rao, MD

Assistant Professor of Medicine, Duke University Medical Center; Director, Cardiac Catheterization Laboratories, Durham VA Medical Center, Durham, North Carolina

Disclosures

Disclosure: Sunil V. Rao, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bristol-Myers Squibb Company; AstraZeneca Pharmaceuticals LP; The Medicines Company; Terumo Medical Corporation; Daiichi Sankyo, Inc.; Eli Lilly and Company
Served as a speaker or a member of a speakers bureau for: Bristol-Myers Squibb Company; sanofi-aventis; The Medicines Company; Terumo Medical Corporation
Received grants for clinical research from: Cordis Corporation; Novartis Pharmaceuticals Corporation; Ikaria, Inc.

Dr. Rao does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr. Rao does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

James B. Hermiller, MD

Director, Cardiac Catheterization Labs, The Care Group, St. Vincent Hospital, Indianapolis, Indiana

Disclosures

Disclosure: James B. Hermiller, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: St. Jude Medical; Boston Scientific; Abbott Laboratories; Medtronic, Inc.
Served as a speaker or a member of a speakers bureau for: Eli Lilly and Company

Dr. Hermiller does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr. Hermiller does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Alan Kadish, MD

Chester C. and Deborah H. Cooley Distinguished Professor of Cardiology and Medicine, Feinberg Cardiovascular Institute, Northwestern University, Chicago, Illinois

Disclosures

Disclosure: Alan Kadish, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: LifeWatch, Corp.; sanofi-aventis
Received grants for clinical research from: St. Jude Medical

Dr. Kadish does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr. Kadish does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor(s)

Ronald K. Miller, PhD

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Ronald K. Miller, PhD, has disclosed no relevant financial relationships.

CME Reviewer(s)

Nafeez Zawahir, MD

CME Clinical Director, Medscape, LLC

Disclosures

Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

Accreditation Statements

For Physicians

Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Cardiology

CME

Prevention of Sudden Cardiac Arrest Post PTCA in High-Risk Patients

Authors: Gregg W. Stone, MD; Sunil V. Rao, MD; James B. Hermiller, MD; Alan Kadish, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME Released: 4/29/2011; Reviewed and Renewed: 9/2/2015

Valid for credit through: 9/2/2016, 11:59 PM EST

processing....

The audio version of this presentation is available for use as a professional resource from Medscape Education.

Download Now

CME Information Download Slides

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Faculty and Disclosures

Moderator(s)

Gregg W. Stone, MD

Panelist(s)

Sunil V. Rao, MD

James B. Hermiller, MD

Alan Kadish, MD

Editor(s)

Ronald K. Miller, PhD

CME Reviewer(s)

Nafeez Zawahir, MD

CME

Prevention of Sudden Cardiac Arrest Post PTCA in High-Risk Patients

Target Audience and Goal Statement

Disclosures

Moderator(s)

Gregg W. Stone, MD

Panelist(s)

Sunil V. Rao, MD

James B. Hermiller, MD

Alan Kadish, MD

Editor(s)

Ronald K. Miller, PhD

CME Reviewer(s)

Nafeez Zawahir, MD

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Prevention of Sudden Cardiac Arrest Post PTCA in High-Risk Patients